Bedi brings significant expertise in strategy, growth, and execution driving technology-enabled innovation across the healthcare industry
“Arjun is an excellent addition to Certara’s board, bringing a powerful combination of technology fluency, growth leadership, and board governance experience,” said Jon Resnick, Chief Executive Officer. “His decades of work with many of the world’s leading pharmaceutical and biotech organizations will be invaluable in supporting greater industry adoption of biosimulation to help speed innovative new medicines to patients.”
“Certara is uniquely positioned at the intersection of biosimulation, AI, and drug development. I’ve seen firsthand how AI-enhanced biosimulation technology can unlock greater certainty in drug development assets while enhancing their commercial performance and patient impact,” said Arjun Bedi. “I'm excited to join the board as Certara is poised for accelerated growth."
关于Certara
Certara accelerates medicines using biosimulation software, technology, and services to transform traditional drug discovery and development. 其客户包括超 2,600 家生物制药公司、学术机构和来自 70 个国家的监管机构。了解更多信息,请访问 www.certara.com.cn。
Certara 联系人:
Sheila Rocchio
[email protected]
媒体联系人:
Alyssa Horowitz
[email protected]
Certara 正在彻底改变药物发现与开发进程
我们变革药物开发,造福人类。我们致力于为创新者、研究人员和监管专家提供量身定制的软件和服务解决方案,以满足他们的需求,从而在整个药物开发生命周期中取得成功。



